PSS34 MODELLING THE LONG-TERM CLINICAL OUTCOMES OF MEDICAL MANAGEMENT OF PRIMARY OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION  by Orme, M et al.
acute OM. Although, considered a minor condition, OM often
disrupts the daily routine, forcing parents to stay at home. This
study was designed to investigate the productivity loss and soci-
etal burden of OM in several European countries. METHODS:
An internet-survey was conducted in 7 EU-countries: France(F),
Great Britain(GB), Germany(D), Spain(E), Italy(I), The Nether-
lands(NL), Belgium(B). Questions regarding the most recent
childhood-illness-episode included: symptoms, medical diagnosis
if medical help was sought, time taken off work, leisure time loss
and diminished productivity at work. Data were analyzed for
OM-episodes. RESULTS: 14916 parents of children (<5-years)
reported a child-illness-episode in the previous year, completing
an e-mailed 17-question-survey. A total of 1479 OM-episodes
were reported (65%–75% occurring in the previous month).
The proportion of parents seeking medical help ranged from
47%(NL) to 88.7%(E). In E, 27.9% of parents went to the
Emergency Room, 10–15% (D,I,GB); 2–4% (NL,B,F). Hospitali-
sation was required for 3.6–7.7% for an average 1.4–6.8 days.
12.8% (F,B)–21.7% (NL) parents took a median of 10–16 hours
off work. A further 23.4% (NL) to 82.4% (UK) parents reported
being less productive at work. In addition, 47.5% (D) to 68.1%
(B) said they had to take time out of their leisure time to visit the
doctor or the pharmacist. Children had an average of 2.2–2.7
episodes in the previous year; 28–57% had had 3 episodes in
the previous year. Indirect costs amounted to a total of €115.36
(NL) to €300.41 (UK) per episode. CONCLUSIONS: Indirect
costs due to lost productivity, either due to time taken off work,
reduced productivity at work or leisure time loss represents a
signiﬁcant proportion of the costs associated with OM. An inter-
vention that would reduce the incidence, prevalence or duration
of OM would have a major impact on the societal burden.
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OBJECTIVES: Several studies have shown that reducing the
intraocular pressure (IOP) of patients with glaucoma to a target
level 18 mmHg prevents further visual ﬁeld deterioration. The
objective of this analysis was to compare the IOP-lowering
efﬁcacy and the cost-effectiveness of ﬁxed combinations of
brimonidine/timolol and dorzolamide/timolol in 10 European
countries. METHODS: Efﬁcacy and safety of the two ﬁxed com-
bination products were based on pooled data from two head-to-
head trials. Efﬁcacy was measured as the percentage of patients
reaching an IOP level 18 mmHg or 13 mmHg after 3 months
of treatment. Discontinuation rates due to adverse events were
also included in the model, and it was assumed that patients
discontinuing treatment had an extra ophthalmologist visit. All
drug costs were market prices inclusive of VAT, and ophthal-
mologist visit costs were priced using ofﬁcial tariffs. RESULTS:
Clinical efﬁcacy data showed that brimonidine/timolol was more
effective than dorzolamide/timolol in terms of lowering patients’
IOP. The percentage of patients reaching IOP 13 mmHg was
32.65% for brimonidine/timolol and 13.95% for dorzolamide/
timolol (p = 0.0359). 77.55% of brimonidine/timolol patients
reached a target IOP  18 mmHg, and 60.47% of dorzolamide/
timolol patients did (p = 0.0756). Three months’ health care
costs for patients treated with brimonidine/timolol were compa-
rable to those of dorzolamide/timolol treatment in the 10 studied
countries. Brimonidine/timolol was less costly and more effective
in Italy, Spain, and Norway, whereas it was more effective and
slightly more costly in Germany, the UK, Denmark, Sweden, the
The Netherlands, Portugal and France. In these countries, the
incremental cost per patient reaching a target IOP  18 mmHg
ranged from £0.32 (UK) to €26.66 (The Netherlands). For IOP
 13 mm Hg the range was £0.29 (UK) to €24.36 (The Nether-
lands). CONCLUSIONS: Brimonidine/timolol is effective in
terms of lowering IOP and is a cost-effective treatment strategy
for patients with glaucoma.
PSS33
THE COST OF UVEITISTREATMENT IN FRANCE:A ONE-YEAR
RETROSPECTIVE ANALYSIS
Kobelt G1, Bodaghi B2, Richard B1, Plesnilla C3, Buchholz P4,
Brézin AP5, Heron E6, Labetoulle M7, Sahel J6
1European Health Economics, Speracedes, France, 2Pitié Salpêtrière,
Paris, France, 3Medical Economics Research Group, Munich, Germany,
4Allergan Europe, Ettlingen, Germany, 5Hôpital Cochin-Université Paris
5, Paris, France, 6CHNO des XV-XX, Paris, France, 7CHU de Bicêtre,
Le Kremlin-Bicêtre, France
OBJECTIVES: To determine current treatment strategies and
evaluate one year consumption of health care resources for
patients with uveitis in France. METHODS: Data abstracted
from charts of consecutive patients (N = 100) from 4 French
referral centers with 12 months follow-up after the ﬁrst visit
included basic demographic data, clinical parameters, and all
disease- or treatment-related resource consumption. Direct
health care costs were estimated using publicly available stan-
dard unit costs. Indirect costs were based on standard sick leave
for each type of inpatient admission or outpatient intervention
and a gender-speciﬁc cost of employment. RESULTS: Most
patients (82%) were below age 60 (retirement age). Patients
had posterior uveitis (36%), panuveitis (33%), chronic anterior
(24%) and intermediate uveitis (7%). Patients received drug
treatments (91%), triamcinolone or dexamethasone injections
(8%), and laser treatment (2%). Mean direct costs per patient
were €3403 ($5045). Inpatient stays accounted for the largest
proportion, with a mean cost of €2889 ($4283) per year. For
patients below 60 years with an admission or intervention, the
estimated average productivity loss was €1750 ($2594), leading
to a mean indirect cost of €830 ($1230) per patient. The esti-
mated total minimum annual costs per patient were €4230
($6271). CONCLUSIONS: Annual treatment costs in this
sample were driven by frequent, extended inpatient stays. This
may be due to the more severely diseased patients who are
treated in these specialized centers. In the current sample, most
patients were of working age, suggesting a substantial amount of
indirect costs arising from sick leave.
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OBJECTIVES: Models have previously focused on short-term
costs and effectiveness measured in terms of intraocular (IOP)
control. This model will assess the long-term effects of continued
medical treatment in terms of glaucoma progression, low vision
and quality-of-life. METHODS: A cost-utility analysis using a
ten-year Markov model of ﬁrst-line latanoprost, bimatoprost,
travoprost or timolol, followed by second / third-line. Transition
probabilities for this model were from a systematic review and
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mixed treatment comparison (MTC). Triggers for treatment
switches included poor compliance (MTC); lack of IOP control
(MTC); or progression of visual ﬁeld defects (3 long-term clinical
trials). Treatment dropouts were from expert opinion and death
rates from UK national data. Follow-up times are from NHS
treatment pathways, drug costs from UK Drug Tariff December
2007, cost of follow-up visits and surgery from NHS National
Tariff 2007/8, and cost of low vision from a published UK
national study. Utilities were from published sources. RESULTS:
Patients were stable on treatment for 64%, 56%, 55% and 54%
of follow-ups for latanoprost, bimatoprost, travoprost and
timolol respectively. As a result, for every 1000 clinic appoint-
ments, 716 patients can be followed-up for a year if treated with
latanoprost compared to 605 for bitmatoprost (similarly versus
other strategies). The total cost of the latanoprost 1st line strat-
egy is £6165, compared to £6239, £6238 and £6083 for bimato-
prost, travoprost or timolol respectively (including surgery costs
and cost of low vision), with 5.87, 5.85, 5.85 and 5.84 QALYs.
The reduction in time spent with low vision for latanoprost is
approximately 2 months compared to the other strategies. CON-
CLUSIONS: The model demonstrates that stablising a patient on
treatment will lead to reduced disease progression and better
outcomes in the long-term, and other beneﬁts such as more
efﬁcient use of scheduled follow-up visits.
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OBJECTIVES: Unilateral cochlear implantation is generally
accepted as a cost-effective intervention for hearing impaired
patients. They gain understanding in quiet conditions, but report
difﬁculties with sound localization and in noisy conditions. These
can be solved with bilateral implants. Currently in Spain, there
are estimated to be about 350 bilateral cochlear implanted
patients. Our objective is to perform an economic evaluation
of bilateral cochlear implantation in adults and children.
METHODS: We reviewed the published literature to ﬁnd the
effectiveness of bilateral cochlear implantation, and costs of the
intervention, to estimate the incremental cost-effectiveness ratio.
Our model only considers costs for public systems described by
the literature. The time horizon considered is the remaining life
of receipients. We use a discount rate of 3% in future costs and
effects. Conditions under which bilateral cochlear implants could
be cost-effective were explored. RESULTS: In adults we ﬁnd that
bilateral cochlear implantation varies from €53,018/QALY when
intervention is simultaneous up to €63.487/QALY, in the case of
sequential mplantation. In children these ratios show more efﬁ-
ciency, from €44,199 to €56.640/QALY, due to the longer time
they can beneﬁt from implants. CONCLUSIONS: Patients who
already have hearing in one ear can obtain advantages from
Bilateral cochlear implantation. It improves their spatial local-
ization of sound and their hearing in noisy circumstances, but it
has limited impact on quality of life measured as QALYs. Sub-
sequently the incremental cost-effective ratio is higher than
usually accepted in public health systems.
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OBJECTIVES: To characterise the epidemiology and outcome
of people hospitalised with a primary diagnosis of psoriasis has
never been characterised previously in the UK. METHODS:
Routine hospital data from a large geographical area (population
approx. 435,000) were record-linked using probability matching
algorithms to mortality data from the Ofﬁce of National Statis-
tics (1991 to 2005). Relative survival was compared using Cox
proportional hazards models. RESULTS: It was possible to iden-
tify 1935 hospital admissions from 1038 subjects; 49% male.
The mean age at ﬁrst admission was 44 years (sd 20). The
minimum, crude prevalence of people hospitalised with psoriasis
at some time was 0.23%. Coincidentally, these admissions rep-
resented 0.23% of all hospital admissions. The crude admission
rate with a primary diagnosis of psoriasis was 2.9 per 10,000
population per year. The proportion of subjects who had only
one admission ranged between 65% and 77%. The median time
between the ﬁrst admission and the second admission was 1.4
years (IQR 0.5 to 3.1). The mean length of hospital stay was 16.8
days (median 15; IQR 8 to 23). There were 55 deaths in total in
this group. Ten year survival was between 94% and 95%. Fol-
lowing standardisation, people admitted more than once had
increased risk of all cause mortality (hazard ratio 2.71; 95% CI
1.39 to 5.31). CONCLUSIONS: This study provides useful back-
ground intelligence on the most severe psoriasis patients. The
proportion of psoriasis patients admitted was estimated to be
about one in six people. Those with more than one admission
with psoriasis—greater psoriasis severity—were associated with
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OBJECTIVES: To identify non compliant glaucoma patients
with the EDSQ, the Eye Drop Satisfaction Questionnaire.
METHODS: Patients were treated for glaucoma or ocular hyper-
tension with either Travatan® or DuoTrav®. Non compliant
patients were identiﬁed with a computerized device (Travalert®)
that collects daily instillation time and number of drops. The
EDSQ was completed once patients used the device for 3 months.
EDSQ included six domains: Concern about treatment, Concern
about disease, Satisfaction with patient-clinician relationship,
Positive beliefs, Treatment convenience, and Declared compli-
ance. Non compliant patients were over-sampled to reach a ratio
1 complier: 1 non complier. A Bayesian network was constructed
to identify non compliers. The “Taboo order” algorithm was
used to estimate associations. Missing data were inferred accord-
ing to the EM structural method. EDSQ scores were dichoto-
mised according to a decision tree aimed at maximising non
complier identiﬁcation. RESULTS: Among the 176 patients who
completed EDSQ, 113 patients used adequately Travalert®. 25
(22.1%) patients were identiﬁed as non complier. No difference
between compliers and non compliers were found on demo-
graphics and baseline medical data. The 6 EDSQ dimensions
were found to be associated directly or indirectly with compli-
ance. The Bayesian network identiﬁed 3 populations whose a
posteriori probabilities were different from a priori. Patients
declaring low compliance, aged <77.5, with a poor patient-
clinician relationship and patients declaring good compliance,
aged >77.5, with a poor patient-clinician relationship were at
A620 Abstracts
